19-08-2015
Pressmaster / Shutterstock.com
Sequenom has requested an en banc review of the US Court of Appeals for the Federal Circuit’s decision to invalidate one of its patents in its dispute with Ariosa Diagnostics, arguing that the decision creates an “existential threat” to patent protection.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
Cooley
European Patent Office
Finnegan LLP
GH Research
Gowling WLG
George Washington Law School
HGF Limited
IQVIA
Kirkland & Ellis International LLP
Marks & Clerk
Mintz Levin
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
Taylor Wessing
The United States Patent and Trademark Office (USPTO)
Valea AB
World Intellectual Property Office
For multi-user price options, or to check if your company has an existing subscription we can add you into for FREE, please contact Atif at achoudhury@newtonmedia.co.
If you have any technical issues please email tech support.
Sequenom; Ariosa; CAFC; Richard Linn; Harmony Test; Mayo v Prometheus Regions: Americas
Sequenom petitions SCOTUS over Ariosa row
22-03-2016
Eyes on Supreme Court after Sequenom rejection
03-12-2015
Sequenom’s en banc petition rejected by Federal Circuit
02-12-2015
Ariosa says the sky is not falling, so Federal Circuit decision must stand
22-10-2015
Sequenom’s en banc bid boosted by support from US professors
02-09-2015
Federal Circuit invalidates Sequenom patent, cites Mayo
17-06-2015
